U.S. Markets closed

Abbott Laboratories (ABT)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
50.80-0.04 (-0.08%)
At close: 4:01PM EDT

50.80 0.00 (0.00%)
After hours: 4:26PM EDT

People also watch
ABBVBMYLLYJNJMRK
Full screen
Previous Close50.84
Open50.81
Bid49.90 x 300
Ask52.00 x 100
Day's Range50.47 - 50.99
52 Week Range37.38 - 51.13
Volume8,584,266
Avg. Volume6,362,514
Market Cap88.15B
Beta1.54
PE Ratio (TTM)52.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.06 (2.08%)
Ex-Dividend Date2017-07-12
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals2 hours ago

    Abbott deal will cost Alere three business units — and untold employees

    When it completes its $5.3 billion acquisition of Waltham-based Alere later this year, Abbott Laboratories will be getting one of the world’s largest makers of point-of-care diagnostic tests, a fast-growing sector. Thanks to antitrust rules, though, Abbott (ABT) will be taking on a slimmed-down version of Alere (ALR) by the end of September. Back in January, Illinois-based Abbott agreed to divest three Alere business units that make competing products in order to secure the approval of European Union antitrust regulators.

  • Market Realist9 hours ago

    Abiomed Expects to Expand Its Presence in This Space

    Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.

  • Market Realist3 days ago

    Abiomed Impella Quality Program Will Boost Demand in Fiscal 2018

    To improve clinical outcomes and increase the number of patients treated in the United States using Impella, Abiomed has launched the Abiomed Impella Quality Program.